Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Rocket Pharmaceuticals, Inc. is not a good growth stock. Tradey thinks it is not wise to invest in Rocket Pharmaceuticals, Inc..
Log in to see more information.
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the develop...
RCKT Fundamental Data by TradingView

News

Rocket Pharmaceuticals appoints Mikael Dolsten, M.D to Board of Directors
Rocket Pharmaceuticals appoints Mikael Dolsten, M.D to Board of Directors

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors
Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors

Business Wire Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...\n more…

Rocket Stock Down More Than 30% in Past Six Months: Here's Why
Rocket Stock Down More Than 30% in Past Six Months: Here's Why

Benzinga Shares of Rocket Pharmaceuticals (NASDAQ: RCKT) have plunged 32.9% in the past six months compared with the industry's decline of 3.4%.\n more…

Rocket Pharmaceuticals (RCKT) Down 10.6% Since Last Earnings Report: Can It Rebound?
Rocket Pharmaceuticals (RCKT) Down 10.6% Since Last Earnings Report: Can It Rebound?

Zacks Investment Research It has been about a month since the last earnings report for Rocket Pharmaceuticals (RCKT). Shares have lost about 10.6% in that time frame, underperforming the S&P 500.Will the recent negative trend...\n more…

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives $51.75 Average Price Target from Brokerages
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives $51.75 Average Price Target from Brokerages

Zolmax Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Get Free Report) have been given a consensus rating of "Moderate Buy" by the ten brokerages that are presently covering the firm, MarketBeat.com...\n more…

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Purchased by Nisa Investment Advisors LLC
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Purchased by Nisa Investment Advisors LLC

Ticker Report Nisa Investment Advisors LLC boosted its stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 31.9% during the second quarter, according to the company in its most recent filing with...\n more…